RAB31

Across TCGA pan-cancer cohorts, RAB31 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAB31 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RAB31 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAB31 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

PDAC, HNSC, and COAD are the cancer types where RAB31 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.558	0.843	<.001	44	view →
HNSC	DFS	Tertile	IV	0.838	0.516	.003	32	view →
COAD	DFS	Median	All	0.878	1.000	.012	24	view →
CCRCC	DFS	Median	II,III,IV	0.235	0.887	.005	24	view →
LUAD	DFS	Median	All	0.828	0.663	.016	9	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAB31–PDAC (DFS)

Open the PDAC breakdown →